Waters and BD Biosciences & Diagnostic Solutions announce $17.5B merger

Waters Corp announced a $17.5 billion Reverse Morris Trust merger with BD Biosciences & Diagnostic Solutions, combining their complementary strengths in chromatography and flow cytometry to form a new life sciences and diagnostics leader. This transaction is projected to double Waters' addressable market to $40 billion, be immediately accretive to adjusted EPS, and yield pro forma 2025 revenues of $6.5 billion and $2.0 billion in adjusted EBITDA. Despite the stated strategic benefits and financial projections, Waters' shares declined 12.4% on the announcement amid investor concerns over the deal's size and potential shareholder dilution, while BD shares saw a more modest 1.6% dip.

Analysis

Waters Corp (WAT) is undertaking a significant strategic transformation through a $17.5 billion Reverse Morris Trust merger with BD's (BDX) Biosciences & Diagnostic Solutions division. Management presents a compelling long-term value proposition, projecting the combination will double Waters' total addressable market to $40 billion, generate pro forma 2025 revenues of $6.5 billion with $2.0 billion in adjusted EBITDA, and be immediately accretive to adjusted earnings per share. The strategic rationale hinges on combining Waters' expertise in chromatography and mass spectrometry with BD's leadership in flow cytometry, aiming to create a dominant player in high-growth, regulated testing markets. However, the market has responded with significant skepticism, evidenced by a 12.4% decline in WAT's shares on concerns over the deal's large scale and potential shareholder dilution. In contrast, BDX shares experienced only a minor 1.6% dip, indicating a neutral market reception for the divesting company. This stark divergence highlights a conflict between the company's long-term strategic vision and immediate investor risk aversion.

Key Decisions for Investors

• For investors in Waters Corp (WAT), the 12.4% share price decline creates a critical decision point, weighing the company's stated long-term strategic benefits and synergy targets against immediate market concerns regarding shareholder dilution and execution risk.
• Prospective investors should closely monitor the combined entity's ability to achieve its pro forma targets, particularly the $6.5 billion in revenue and the projected 5-7% market growth, as delivering on these metrics will be key to reversing the negative sentiment.
• For Becton, Dickinson and Co. (BDX) shareholders, this transaction is primarily a strategic divestiture, and the market's neutral reaction suggests focus should now shift to the operational and financial profile of the remaining core BDX business.